((自动化翻译由路透提供，请见免责声明 ))
9月25日 - ** 比利时生物技术公司Argenx 股价上涨4%，KBC分析师称，尽管竞争对手的试验数据良好，但该公司的Vyvgart药物仍是最有力的竞争者
** 安进 周二报告了其 Uplizna 药物治疗罕见肌肉衰弱性疾病肌无力的第三阶段数据， (link)。
** KBC说："我们认为Uplizna的数据集很强大，但与Vyvgart相比稍逊一筹。
** KBC补充说："Vyvgart在第4周已经显示出很强的疗效，因此在第26周的疗效超过了Uplizna。
** 如果涨势持续，该股将创下 8 月 9 日以来的最佳表现，超过比利时蓝筹股 BEL 20 指数 <.BFX
** 包括周三的涨幅在内，该股今年累计上涨了 42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.